About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Jubilant Pharmova Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Duties of Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Investors Meet
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
About Us
Company Profile
Vision Values & Promise
Management
Board of Directors
Shyam S Bhartia
Hari S Bhartia
Sushil Kumar Roongta
Vivek Mehra
Arun Seth
Shirish G. Belapure
Shivpriya Nanda
Harsh Mahajan
Priyavrat Bhartia
Arjun Shanker Bhartia
Arvind Chokhany
Dr. Ramakrishnan Arul
Executive Leadership Team
Locations Worldwide
Subsidiaries
Group Ombudsperson
Business Segments
Radiopharma
Allergy Immunotherapy
CDMO Sterile Injectables
Contract Research Development & Manufacturing Organisation
Drug Discovery Service
Active Pharmaceutical Ingredients
Generics
Proprietary Novel Drugs
Business Enablers
Manufacturing
R&D and Intellectual Property
Business Excellence
Human Resource
Supply Chain
Investors
Financials
Quarterly Results
Investor Presentation
Annual Reports
Annual Return
Subsidiaries Accounts
Intimation to Stock Exchanges
Jubilant Pharmova Investor Meets
Stock Information
Share Price Graph
Historical Share Price
Analyst Coverage
Listing
Sub Division of Shares
Equity History
Investor Information
Change of Name
Scheme of Arrangement
Share Holding Pattern
Share Transfer Information
Distribution Pattern
Dividend Payment
Cost Spilit Letter
FAQs
Forms
Updation of KYC details
Credit Ratings
Corporate Governance
Philosophy
Board Structure
Policies and Codes
Policy on Materiality of Related Party Transactions and Dealing with Related Party Transactions
Policy on Board Diversity
Policy for Determining Material Subsidiaries
Whistle Blower Policy
Corporate Social Responsibility Policy
Code of Conduct for Directors and Senior Management
Code for Independent Directors
Appointment and Remuneration Policy
Familiarisation Programme for Independent Directors
Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information
Policy for Determination of Materiality of Events and Information
Archival Policy
Dividend Distribution Policy
Silent Period Policy
Corporate Tax Policy
Grievance Redressal policy
Risk Management Policy
Duties of Directors
Independence Criteria for Directors
Postal Ballot
Unclaimed Dividend & Shares
Investor Feedback Form
Investor Contact
Nodal Officer
Institutional Investors
Investor Grievances
Registrar and Transfer Agent
KMP - Reg. 30
Investors Meet
Disclosure
Online Dispute Resolution
Sustainability
Overview
Corporate Social Responsibility
Sustainable Development Goals
Safety and Occupational Health
Stakeholder Engagement
Environment
Environmental Compliance
Fly Ash Stock Report
Policies
Climate Change Mitigation and Energy Conservation Policy
Environmental, Health and Safety Policy
Sustainability Policy
Biodiversity Policy
Biomedical Waste Information
Sustainability Report
Sustainability Contact
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
News
Careers
Global Opportunities
Code of Conduct
Fraud Alert Statement
Fun at Work
Diversity and Inclusion
Campus Hiring
Policies
Downloads
Brochures
Annual Report
Sustainability Report
Contact
Addresses
Enquiry Form
What are you looking for?
×
Disclosoures under 30(8)
Home
Disclosoures under 30(8)
Disclosoures under 30(8)
2024 - 25
Q4
Update on Acquisition of Stake in Jasmin - March 20, 2025
Clarification on news articles - February 25, 2025
USFDA Communication – Update on Cadista – March 12, 2025
Stock Exchange Disclosure Audio Recording - February 24, 2025
Jubilant Pharmova Stock Exchange Disclosure - February 24, 2025
Investors Meet – February 10, 2025
Newspaper publication of Financial Results – February 1, 2025
Press Release and Presentation Q3 Results FY 2025 – January 31, 2025
Prepayment of loan - USD 25 million (24.01.2025)
Investors Meet – February 24, 2025
USFDA Communication – Cadista- January 16, 2025
Q3
Credit Rating – December 10, 2024
Deferment of Investors Meet – November 12, 2024
Newspaper publication of Financial Results – October 26, 2024
Press Release and Presentation Q2 Results FY 2025 – October 25, 2024
Q2 Results FY 2025 – October 25, 2024
Acquisition of Stake in Jasmin – October 4, 2024
Q2
USFDA Communication – Montreal – September 28, 2024
USFDA Communication – Spokane – September 26, 2024
Investors Meet – September 19, 2024
USFDA Communication – Spokane – September 10, 2024
Investors Meet – August 22, 2024 and August 23, 2024
Stock Exchange disclosure – Signing of ‘Put Option Offer’ between Jubilant Biosys Innovative Research Services Pte Limited and Pierre Fabre Laboratories– 16.08.2024
Stock Exchange disclosure for resignation of Senior Management Personnel – August 2, 2024
Stock Exchange disclosure for receipt of orders from Income Tax Department w.r.t. Jubilant Generics Limited – 27.07.2024
Newspaper publication of Financial Results – July 20, 2024
USFDA Communication - Montreal – July 19, 2024
Q1 Results FY 2025 – July 19, 2024
Q1
Newspaper Advertisement for dispatch of communication sent to shareholders relating to notice of transfer of equity shares to Investor Education and Protection Fund - June 20, 2024
USFDA Communication – Montreal (18.06.2024)
Investor Meet - June 18, 2024
USFDA communication Spokane - June 07, 2024
Update on Acquisition of stake in O2 Renewable Energy XVI Private Limited - June 06, 2024
Update on Jubilant Pharmova Disclosure (Sofie) - June 05, 2024
Q4 Results FY 2024 - May 29, 2024
Declaration of Dividend - May 29, 2024
Change of Directors - May 29, 2024
Acquisition of Stake in Isharays Energy Two Private Limited - May 28, 2024
Newspaper Advertisement for dispatch of Postal Ballot Notice – May 27, 2024
Update on Stock Exchange disclosure for receipt of orders from Income Tax Department
USFDA Audit Updates - April 24, 2024
Jubilant Cadista Disclosure - April 18, 2024
USFDA Communication - April 17, 2024
Stock exchange disclosure for receipt of orders from Income tax department
Update on acquisition of stake in O2 Renewable Energy XVI Private Limited
2023 - 24
Q4
Change in Independent Directors of the Company
Credit Rating – 22.03.2024
Investor Meet – March 12, 2024 – Update
Investor Meet – March 12, 2024
Newspaper publication of Financial Results – February 03, 2024
USFDA Communication – February 02, 2024
Acquisition of Stake in O2 Renewable Energy XVI Private Limited – January 2, 2024
Q3
Q3 Results FY 2024 – February 02, 2024
Press Release and Presentation Q3 FY 2024 - February 02, 2024
Newspaper Advertisement for dispatch of Postal Ballot Notice – December 26, 2023
Trading Window Closure – December 26, 2023
Postal Ballot Notice – December 21, 2023
USFDA Communication – November 10, 2023
Newspaper publication of Financial Results- October 28, 2023
Press Release and Presentation Q2 FY 2024 - October 27, 2023
Q2 Results FY 2024 – October 27, 2023
Q2
Disclosure of continuing event or information (i.e. ongoing litigations)- August 14, 2023
Newspaper disclosure of TDS- August 14, 2023
Newspaper publication of AGM Notice- August 9, 2023
Newspaper Publication of Pre-Dispatch of AGM Notice – August 7, 2023
Re-appointment of Mr. Arun Seth as Independent Director
Appointment of M/s. Walker Chandiok & Co. LLP as Statutory Auditors
45th AGM proceedings, Voting Results and Scrutinizers’ Report
Secretarial Audit Report - Jubilant Generics Limited - FY 2022-23
Secretarial Audit Report - Jubilant Generics Limited - FY 2021-22
Postal Ballot Notice - July 22, 2023
Newspaper publication of Financial Results- July 20, 2023
Postal Ballot Notice - July 20, 2023
ESOP Disclosure - July 19, 2023
Q1 Results FY 2024 - July 19, 2023
Press Release and Presentation Q1 FY 2024 - July 19, 2023
Newspaper Advertisement for transfer of shares to IEPF – July 2, 2023
Q1
Investor Meet - May 30, 2023
Change of Directors and CFO - May 30, 2023
USFDA Communication - May 29, 2023
Q4 Results FY 2023 - May 29, 2023
Declaration of Dividend - May 29, 2023
Newspaper Advertisement for Loss of Share Certificate- May 15, 2023
Outcome of Postal Ballot - Appointment of Mr. Shirish G. Belapure as an Independent Director - April 13, 2023
2022 - 23
Q4
Loan Facility by Government of Canada - March 16, 2023
Newspaper Advertisement for Dispatch of Postal Ballot - March 14, 2023
Postal Ballot Notice - March 13, 2023
Appointment of Director – March 8, 2023
USFDA Communication - March 8, 2023
Stock Exchange Disclosure Con-call transcript - February 9, 2023
Appointment of Statutory Auditors - February 4, 2023
Investor Call Audio Recording - February 3, 2023
Q3 Results FY 2023 - February 3, 2023
Revised Con Call Invite - February 1, 2023
USFDA Approval - January 31, 2023
Investors’ Con-Call Intimation - January 27, 2023
Q3
Credit Rating - December 27, 2022
Trading Window Closure - December 23, 2022
Press release - December 14, 2022
Clarification to NSE - December 12, 2022
Newspaper advertisement for loss of Share Certificates - December 5, 2022
Jubilant Pharmova Employees Stock Option Plan 2018 - Grant of Stock Options - November 17, 2022
Outcome of Postal Ballot - Amendment of Jubilant Pharmova Employees Stock Option Plan 2018 - November 14, 2022
Stock Exchange Disclosure Con-call transcript - October 31, 2022
Press Release - October 29, 2022
Newspaper advertisement for financial results - October 22, 2022
Investor Call Audio Recording - October 22, 2022
Newspaper Publication of Postal Ballot Notice - October 17 2022
Notice of Postal Ballot - October 15, 2022
Q2
Appointment of Dr. Jaidev Rajpal as Head of Generics business
Annual General Meeting Transcript - September 26, 2022
Intimation of Trading Window Closure - September 23, 2022
USFDA Communication - August 26, 2022
Stock Exchange Disclosure Con- Call Transcript- August 8, 2022
Newspaper publication of Financial Results - August 05, 2022
Grant of ESOP - August 2, 2022
USFDA Audit - August 2, 2022
Investor Call Audio Recording - August 2, 2022
Investors’ Con-call Intimation - August 2, 2022
Early Redemption of 6% Senior Notes by Jubilant Pharma Limited
Early Redemption of Senior Notes Due in 2024 by Jubilant Pharma Limited
Intimation of Dividend Record Date - July 29, 2022
Loan agreement with Standard Chartered Bank - July 13, 2022
USFDA Communication - July 13, 2022
Clarification regarding Volume - July 08, 2022
Newspaper Publication w.r.t. Notice of Transfer of shares to IEPF - July 01, 2022
Appointment of WTD - July 1, 2022 and CS - August 1, 2022
Q1
Expansion of CMO Manufacturing facility at Montreal, Canada and Government of Quebec funding through a loan
Update on Investors or Analysts Meeting
Trading Window Closure - June 23, 2022
NCLT Final Order - June 13, 2022
Letter to SEs - Transcript of Earnings Conference Call BM - June 2, 2022
Investors’ Meet - June 1, 2022
Stock Exchange Intimation Audio Recording May 28, 2022
Cooperative agreement of US$149.6 Million with US Government - May 28, 2022
Dividend FY 2022 - May 27, 2022
NCLT Order Scheme of Arrangement - May 25, 2022
Intimation of Board Meeting - May 20, 2022
Schedule of Investor Conference Call - May 20, 2022
Outcome of Postal Ballot - Alteration of Articles of Association - May 17, 2022
Postal Ballot Notice - April 16, 2022
Investors’ Meet - April 4, 2022
Greencure Investment - April 2, 2022
2021 - 22
Q4
Credit Rating - February 16, 2022
Investor Meet - March 14, 2022
Investors' Con-call Intimation - January 27, 2022
Investors’ Meet - March 30, 2022
NCLT Convened Meetings - Proceedings and Scrutinizer Reports - January 15, 2022
USFDA ANDA Approval - March 17, 2022
Q3
Groundbreaking Ceremony for expansion of Spokane Facility - November 11, 2021
Investors’ Con-call Intimation - October 14, 2021
Investors’ Meet - November 15, 2021
Trading Window Closure - December 24, 2021
Q2
AGM Proceedings - September 22, 2021
Board approval for API Demerger - July 23, 2021
Employees Stock Option Plan 2018 - July 23, 2021
Intimation of Dividend Record Date - July 27, 2021
Investor Meet - September 23, 2021
Investors’ Con-call Intimation - July 15, 2021
Investors’ Meet - August 16, 2021
Investors’ Meet - August 21, 2021
Investors’ Meet - August 31, 2021
Trading Window Closure - September 23, 2021
US FDA Import Alert on Roorkee Facility - July 15, 2021
Voting Results of Annual General Meeting - September 22, 2021
Q1
Appointment of WTD and CFO - April 1, 2021
Closure of Trading Window - June 22, 2021
Dividend FY 2021 - June 4, 2021
Expansion of Spokane Facility - May 31, 2021
Intimation of transfer of shares in physical mode in terms of SEBI Circular dated November 6, 2018
Investor Meet Invite - June 10, 2021
Investors’ Con-call Intimation - May 28, 2021
Investors’ Meet and Presentation - June 23, 2021
Investors’ Presentation - June 18, 2021
JPL wins Bracco's Legal Appeals - May 8, 2021
Manufacturing Partnership for COVID-19 Vaccine - June 15, 2021
Update on Credit Ratings - May 7, 2021
Update on Credit Ratings - May 27, 2021
Update on Remdesivir - April 19, 2021
2020 - 21
Q4
Change in Directors - February 6, 2021
Closure of Trading Window - March 24, 2021
Demerger and Change of Name - February 1, 2021
Investors’ Con-call Intimation - January 29, 2021
JPL Bonds Redemption - January 30, 2021
JPL Bonds Redemption - March 5, 2021
NCLT Certified Order - January 6, 2021
Notice of Early Redemption of Bonds by JPL - February 3, 2021
Outcome of Restructuring Committee Meeting - January 8, 2021
Outcome of Restructuring Committee Meeting - January 18, 2021
Record Date for Demerger - January 21, 2021
Q3
Closure of Trading Window - December 24, 2020
Composite Scheme - NCLT Order - December 24, 2020
Credit Rating - October 31, 2020
Investment in Sofie - November 4, 2020
Investors Meet - December 2, 2020
Investors Meet - December 14, 2020
Investors’ Con-call Intimation - October 28, 2020
Issuance of Commercial Papers of Rs. 30 Crore - October 9, 2020
Issuance of Commercial Papers of Rs. 90 Crore - October 12, 2020
Issuance of Commercial Papers of Rs. 90 Crore - November 26, 2020
Notice of Partial Early Redemption of Bonds by JPL - December 30, 2020
Stock Exchange Disclosure - Investor Meet - November 10, 2020
Q2
Closure of Trading Window - September 22, 2020
Intimation of Investor Meet - September 22, 2020
Investors' Con-call Intimation - August 28, 2020
Outcome of Annual General Meeting - September 11, 2020
Outcome of NCLT Convened Meetings of the Equity Shareholders, Secured Creditors and Unsecured Creditors - August 9, 2020
Resignation of Chief Financial Officer - September 4, 2020
Stock Exchange Disclosure - Credit Rating - August 19, 2020
Stock Exchange Disclosure - Intimation of Annual General Meeting - August 19, 2020
Stock Exchange Disclosure approval of ‘JUBI-R’ (remdesivir) - July 20, 2020
Stock Exchange Disclosure Commercial Papers - August 18, 2020
Stock Exchange Disclosure launch of ‘JUBI-R’ (remdesivir) - August 3, 2020
Q1
Issuance of Commercial Papers of Rs. 50 Crore - June 12, 2020
Issuance of Commercial Papers of Rs. 50 Crore - June 19, 2020
JLL Stock Exchange Disclosure - Agreement with Gilead May 12, 2020
JLL Stx - Closure of Trading Window - June 23, 2020
Notice of NCLT Convened Meeting of Equity Shareholders - July 3, 2020
Notice of NCLT Convened Meeting of Secured Creditors - July 3, 2020
Notice of NCLT Convened Meeting of Unsecured Creditors - July 3, 2020
Schedule of Investor Conference Call - May 25, 2020
Stock Exchange Disclosure - Credit Rating - May 30, 2020
Stock Exchange Disclosure Commercial Papers April 17, 2020
Stock Exchange Disclosure Credit Rating April 10, 2020
Stock Exchange Disclosure Non Deal Roadshow - June 11, 2020
2019 - 20
Q4
Closure of Trading Window March 24, 2020
Investors Meet - January 23, 2020
Outcome of Board Meeting - Declaration of Dividend - February 27, 2020
Schedule of Investor Conference Call - January 23, 2020
Stock Exchange Disclosure Investor Conference Call Invite March 31, 2020
Stock Exchange Disclosure receipt of EIR from USFDA March 31, 2020
Q3
Approval of the Composite Scheme of Arrangement - October 25, 2019
Credit Rating by CRISIL - November 1, 2019
Credit Rating by India Ratings and Research - November 5, 2019
JPL Early Redemption of Bonds - November 21, 2019
MOFCOM, China terminates anti-dumping duty - November 20, 2019
Partial Early Redemption of Bonds by JPL - October 21, 2019
Payment of Penalty to SEBI - November 23, 2019
SAT order against the SEBI Adjudication Order - November 8, 2019
Schedule of Investor Conference Call - October 17, 2019
Slump Sale of IBP Business to JGL - October 25, 2019
USFDA Approval - October 22, 2019
Q2
Closure of Trading Window - September 23, 2019
Issuance of Commercial Paper of Rs. 40 Crore - August 2, 2019
JLL Restructuring - July 26, 2019
Proceedings of 41st Annual General Meeting - September 25, 2019
Schedule of Investor Conference Call - July 19, 2019
Voting Results of 41st Annual General Meeting - September 26, 2019
Q1
Disclosre regarding transfer of shares of JBL - June 7, 2019
Issuance of Commercial Paper of Rs. 40 Crore - June 25, 2019
Issuance of Commercial Paper of Rs. 100 Crore - April 18, 2019
Notice for closure of Trading Window - June 21, 2019
Recommendation of Dividend of Rs. 4.50 per Equity Shares - May 17, 2019
RPT Disclosure for FY 2019 - June 13, 2019
Schedule of Investor Conference Call - May 9, 2019
2018 - 19
Q4
Additional Information - JPL Bond Issue Proposal - February 25, 2019
Approval for payment of Corporate Brand Royalty to Jubilant Enpro Private Limited - February 5, 2019
Board Approval for revision in the Code of Practices and Procedures for Fair Disclosure - March 29, 2019
Clarification regarding payment of Corporate Brand Royalty - February 5, 2019
Issuance of Bond of US$200 million by JPL - March 5, 2019
Issuance of Commercial Papers of Rs. 75 crore - February 20, 2019
Issuance of Commercial Papers of Rs. 100 Crore - January 25, 2019
JLL_Biosys_OCPS Conversion - February 1, 2019
JLL_Chemsys_OCPS Conversion - February 1, 2019
JPL Bond Issue proposal - February 25, 2019
Listing of Bond by JPL on Singapore Stock Exchange - March 6, 2019
Notice of Investor Meetings (Non-Deal Roadshow) - February 13, 2019
Notice of Investor or Analyst Meetings on March 6, 2019 - March 5, 2019
Notice regarding closure of Trading Window - March 22, 2019
Pricing and Rating of JPL Bond issue - February 28, 2019
Redemption of Zero coupon convertible loan of IFC by JPL - March 29, 2019
Schedule for Investor Conference Call - January 25, 2019
USFDA Inspection Update - API facility at Nanjangud - March 21, 2019
USFDA warning letter for Roorkee facility - March 8, 2019
Q3
Acquisition of Common Stock in Inipharm Inc., USA - November 30, 2018
Closure of Trading Window - December 21, 2018
Disclosure regarding Acquisition of Equity Shares by DDDSL, Singapore - November 29, 2018
Schedule for Investor Conference Call - October 15, 2018
USFDA inspection update for solid dosage formulation facility at Roorkee - December 8, 2018
Q2
Credit Rating by India Ratings and Research - August 23, 2018
Initiation of I-131 MIBG OPTIMUM Trials - July 20, 2018
Notice of 40th Annual General Meeting - August 31, 2018
Notice of Postal Ballot - July 6, 2018
Proceedings of 40th Annual General Meeting - September 26 2018
Schedule for Investor Conference Call - July 20, 2018
Update of JPL IPO - July 27, 20188
Voting Results of 40th Annual General Meeting - September 27, 2018
Voting results of Postal Ballot and Scrutinizer's Report - August 7, 2018
Q1
ANDA Approval for Niacin Extended-Release Tablets USP - May 15, 2018
Credit Rating by CRISIL - June 25, 2018
Issuance of Commercial Papers of Rs. 75 Crore - April 23, 2018
Issuance of Commercial Papers of Rs. 75 crore - June 8, 2018
Issuance of Commercial Papers of Rs. 80 Crore - May 10, 2018
Notice for Schedule of Investor or Analyst meetings - June 11, 2018
Recommendation of Dividend of Rs. 3 per Equity Shares - May 9, 2018
Update on SEBI Adjudication order - April 25, 2018
2017 - 18
Q4
ANDA approval for Amantadine Hydrochloride Tablets - February 9, 2018
Changes in the Board of Directors - January 17, 2018
Disclosure in Form C under SEBI(PIT) Regulations, 2015 - January 25, 2018
Issuance of Commercial Paper of Rs. 90 Crore - January 17, 2018
JLL Response on SEBI Order - February 1, 2018
Notice of Investor or Analyst Meetings - March 8, 2018
Order of Commissioner of State Excise, Maharashtra - March 4, 2018
Stay of Order of Commissioner of State Excise, Maharashtra by Home Dept., Govt. of Maharashtra - March 7, 2018
Q3
Issuance of Commercial Papers of Rs. 50 Crore - October 17, 2017
Issuance of Commercial Papers of Rs. 50 Crore
Share Acquisition by DDDSL - November 22, 2017
USFDA for DRAXIMAGE® DTPA - December 28, 2017
Q2
Acquisition of Radiopharmacy business of Triad - September 1, 2017
Health Canada Approval - September 29, 2017
Notice for closure of Trading Window - September 21, 2017
Notice of Investor or Analyst Meetings - August 1, 2017
Notice of Investor or Analyst Meetings - September 4, 2017
Notice of Investor or Analyst Meetings - September 19, 2017
Notice of Investor or Analyst Meetings - September 25, 2017
Schedule of Investor Conference Call - October 18, 2017
USFDA Approval for Bupropion Hydrochloride Extended-Release Tablets - July 6, 2017
USFDA Approval for Drax Exametazime - August 21, 2017
USFDA Approval for Indomethacin Capsules USP - August 28, 2017
USFDA Approval for Indomethacin Capsules USP - August 28,2017
USFDA approval for Tizanidine Hydrochloride Capsules - August 5, 2017
Voting Results of 39th AGM - August 29, 2017
Q1
Appointment of Directors - May 24, 2017
Credit Rating by Crisil and India Ratings and Research Private Limited - May 2, 2017
Credit Rating by India Rating and Research Private Limited - April 13, 2017
Issuance of Commercial Papers of Rs. 75 Crore - April 27, 2017
Issuance of Commercial Papers of Rs. 100 Crore - April 18, 2017
NGT order for Cease of Operation at Gajraula Plant - April 27, 2017
NGT Order for Gajraula Plant - June 1, 2017
Notice for clsoure of trading window - June 21, 2017
Recommendation of Dividend of Rs. 3 per Equity Shares - May 23, 2017
USFDA Approval for Amlodipine and Olmesartan Medoxomil Tablets - May 17, 2017
USFDA Approval for Olmesartan Medoxmil Tables - April 25, 2017
Vitamin B3 Price increase update - May 25, 2017
2016 - 17
Q4
Announcement for signing of long term contract in Radiopharma business - January 4, 2017
Approval for acquisition of OCPS of JBL - February 7, 2017
Changes in Board of Directors - February 7, 2017
Credit Rating from India Ratings and Research Private Limited - January 25, 2017
Disclsoure with details for issue of NCDs - January 27, 2017
Issuance of Commercial Papers of Rs. 40 Crore - February 28, 2017
Issuance of Commercial Papers of Rs. 50 Crore - January 5, 2017
Issuance of Commercial papers of Rs. 50 Crore - January 24, 2017
Issuance of Commercial Papers of Rs. 50 Crores - January 11, 2017
Issuance of NCDs - January 27, 2017
Notice of Investors or Analysts meetings - February 28, 2017
Notive for closure of Trading Window - March 15, 2017
Proposal to consider acquisition to Speciality Pharma business in USA - March 21, 2017
USFDA approval for Celecoxib Capsules - April 6, 2017
USFDA Approval for Itraconaxole capsules - February 27, 2017
Q3
15% Price increase of Beta Picoline - December 20, 2016
Australian approval for Lyophilized kit for the preparation of Tc 99m MAA Injection - October 5, 2016
Clarification regarding issuance of Commercial papers of Rs. 50 Crore - November 9, 2016
Completion of issue of Bonds by JPL - October 6, 2016
Credit Rating by India Ratings and Research Private Limited - October 4, 2016
Issuance of Commercial papers of Rs. 50 Crore - November 9, 2016
Issuance of Commercial papers of Rs. 50 Crore - October 14, 2016
JPL - Offering Memorandum
Listing of Bond by JPL- October 7, 2016
Notice of schedule of JPL Meeting - November 15, 2016
Proposal to consider issue of NCDs - October 24, 2016
USFDA Approval for Darifenacin ER Tablets - October 13, 2016
USFDA Approval for RUBY-FILL- Rubidium 82 Generator and Elution system - October 3, 2016
Q2
Clarification by JLL - September 27, 2016
Issue of Bond by JPL - September 29, 2016
Proposal to issue Bond by JPL - September 23, 2016
USFDA approval for Telmisarta tablets - August 24, 2016
Q1
Notice of Investors Analysts Meetings - June 28, 2016
Resignation of Director - May 24, 2016